Voriconazole in the treatment of fungal eye infections: A review of current literature

British Journal of Ophthalmology

Volumn 92, Issue 7, 2008, Pages 871-878

  Hariprasad, S M ^a   Mieler, W F ^a   Lin, T K ^a   Sponsel, W E ^b   Graybill, J R ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NATAMYCIN; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ACREMONIUM; ACREMONIUM ALABAMENSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BLASTOMYCES DERMATITIDIS; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COCCIDIOIDES IMMITIS; CRYPTOCOCCUS NEOFORMANS; CURVULARIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; ENDOPHTHALMITIS; EYE; FUNGAL EYE INFECTION; FUNGAL STRAIN; FUSARIUM; HISTOPLASMA CAPSULATUM; HUMAN; KERATOMYCOSIS; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PAECILOMYCES; PENICILLIUM MARNEFFEI; PRIORITY JOURNAL; RASH; REVIEW; SCEDOSPORIUM APIOSPERMUM; TREATMENT OUTCOME; VISUAL DISORDER;

ANIMALS; ANTIFUNGAL AGENTS; EYE INFECTIONS, FUNGAL; HUMANS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 47049088124     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.136515     Document Type: Review

References (52)

1. Centers for Disease Control (CDC). Update: Fusarium keratitis-United States, 2005-2006. Morb Mortal Wkly Rep 2006;55:563-4.
2. Gupta A, Gupta V, Gupta A, et al. Spectrum and clinical profile of post cataract surgery endophthalmitis in north India. Indian J Ophthalmol 2003;51:139-45.
3. Sharma S, Srinivasan M, George C. The current status of Fusarium species in mycotic keratitis in South India. J Med Microbiol 1993;11:140-7.
4. Marangon FB, Miller D, Giaconi JA, et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004;137:820-5.
5. Vajpayee RB, Gupta SK, Bareja U, et al. Ocular atopy and mycotic keratitis. Ann Ophthalmol 1990;22:369-72.
6. O'Day DM, Head WS, Robinson RD, et al. Intraocular penetration of systemically administered antifungal. Curr Eye Res 1985;4:131-4.
7. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 2005;49:5136-8.
8. Gupta AK, Kohli Y, Batra R. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and nondermatophyte species. Med Mycol 2005;43:179-85.
9. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.
10. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21.
11. Ullmann AJ, Comely OA, Burchardt A, et al. Pharmacokinetics, safety and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
12. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150:101-15.
13. Ghannoum MA, Kuhn DM. Voriconazole: Better chances for patients with invasive mycoses. Em J Med Res 2002;7:242-56.
14. Marco F, Pfaller MA, Messer SA, et al. Antifungal activity of a new triazole, voriconazole (UK-109,496], compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998;36:433-6.
15. Sabo JA, Abdel-Rahman SM. Voriconazole: A new triazole antifungal. Ann Pharmacother 2000;34:1032-43.
16. Maesaki S, Iwakawa J, Higashiyama Y, et al. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus. J Infect Chemother 2000;6:101-3.
17. Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999;37:2343-5.
18. Hoffman HL, Rathburn RC. Review of the safety and efficacy of voriconazole. Expert Opin Invest Drugs 2002;11:409-29.
19. Herbrecht R, Denning D, Patterson T, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin ß for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
20. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
21. Gao H, Pennesi M, Shah K, et al. Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 2003;101:183-90.
22. Aydin S, Ertugrul B, Gultekin B, et al. Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis 2007;7:87.
23. Chen FK, Chen SD, Tay-Kearney ML. Intravitreal voriconazole for the treatment of endogenous endophthalmitis caused by Scedosporium apiospermum. Clin Exp Ophthalmol 2007;35:382-5.
24. Figueroa MS, Fortun J, Clement A, et al. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina 2004;24:319-20.
25. Hernandez Prats C, Llinares Tello F, Burgos San Jose A, et al. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 2004;38:414-17.
26. Huynh TK, Lee LR, Ellis D. Late-onset post-traumatic Phaeoacremonium parasiticum endophthalmitis. Clin Exp Ophthalmol 2007;35:366-8.
27. Jang JG, Kim KS, Shin WS, et al. Treatment of Candida chorioretinitis with voriconazole. Korean J Ophthalmol 2005;19:73-6.
28. Jain A, Egbert P, McCulley TJ. Endogenous Scedosporium apiospermum endophthalmitis. Arch Ophthalmol 2007;125:1286-9.
29. Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006;113:1184-6.
30. Nehemy MB, Vasconcelos-Santos DV, Torqueti-Costa L, et al. Chronic endophthalmitis due to Verticillium species after cataract surgery treated (or managed) with pars plana vitrectomy and oral and intravitreal voriconazole. Retina 2006;26:225-7.
31. Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis. Retina 2006;26:935-9.
32. Varma D, Thaker HR, Moss PJ, et al. Use of voriconazole in Candida retinitis. Eye 2005;19:485-7.
33. Yildiran ST, Mutlu FM, Saracli MA. Fungal endophthalmitis caused by Aspergillus ustus in a patient following cataract surgery. Med Mycol 2006;44:665-9.
34. Zarkovic A, Guest S. Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole. Int Ophthalmol 2007;27:391-4.
35. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-7.
36. Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-40.
37. Vemulakonda GA, Hariprasad SM, Mieler WF. et al. Aqueous and vitreous concentration following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008;126:18-22.
38. Nulens E, Eggink C, Rijs AJ, et al. Keratitis caused by Scedosporium apiospermum successfully treated with a corneal transplant and voriconazole. J Clin Microbiol 2003;41:2261-4.
39. Klont RR, Eggink CA, Rijs AJMM, et al. Successful treatment of Fusarium keratitis with corneal transplantation and topical and systemic voriconazole. Clin Infect Dis 2005;40:e110-12.
40. Sponsel W, Chen N, Dang D, et al. Topical voriconazole as a novel treatment for fungal keratitis. Antimicrob Agents Chemother 2006;50:262-8.
41. Sponsel WE, Graybill JR, Nevarez HL, et al. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002;86:829-30.
42. Tu EY, McCartney DL, Beatty EF, et al. Successful treatment of resistant ocular fusariosis with posaconazole. Am J Ophthalmol 2007;143:222-7.
43. Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal voriconazole. Br J Ophthalmol 2000;84:932-3.
44. Scott IU, Cruz-Villegas V, Flynn HW, et al. Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am J Ophthalmol 2004;137:583-5.
45. Garbino J, Ondrusova A, Baligvo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002;34:701-3.
46. Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003;121:735-7.
47. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005;140:552-4.
48. Marr KA, Boechk M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797- 802.
49. Verma S, Tuft SJ. Fusarium solani keratitis following LASIK for myopia. Br J Ophthalmol 2002;86:1190-1.
50. Polizzi A, Siniscalchi C, Mastromarino A, et al. Effect of voriconazole on a corneal abscess caused by Fusarium. Acta Ophthalmol Scand 2004;82:762-4.
51. Jhanji V, Sharma N, Mannan R, et al. Management of tunnel fungal infection with voriconazole. J Cataract Refract Surg 2007;33:915-17.
52. Jones A, Muhtaseb M. Use of voriconazole in fungal keratitis. J Cataract Refract Surg 2008;4:183-4.